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ABSTRACT 
 
The combined effect of hydroxypropyl-β-cyclodextrin (HPβCD) and polyvinylpyrrolidone (PVP) or sodium 
carboxymethylcellulose (CMC) on the solubility of pyrimethamine (PYR) was studied. Equimolar PYR–HPβCD 
solid systems, in the presence or the absence of 0.25% (w/v) PVP or 0.10% (w/v) CMC were prepared by 
coevaporation or freeze-drying, and characterized by differential scanning calorimetry, X-ray diffraction analysis 
and dissolution profile. Phase-solubility analysis was used to investigate the interactions in aqueous solution 
between PYR and HPβCD, in the absence or presence of polymers, which showed a linear increase of PYR 
solubility depending on the concentration of HPβCD. The presence of polymer did not alter the stoichiometry of the 
complexes. DSC results were indicative of complexation, due to the loss of the characteristic endothermic peak of 
PYR. X-ray diffraction analysis confirmed the DSC results. Binary and ternary complexes showed higher dissolution 
rate when compared with the pure drug. 
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INTRODUCTION 
 
The pharmaceutical importance of CDs 
(cyclodextrins) as excipients, used for improving 
the formulation performance, is recognized by 
many regulatory agencies (Mura et al., 2001). 
However, for many reasons that include cost, 
production and toxicology, the amount of CDs - 
that could be incorporated in the pharmaceutical 
products is limited (Valero et al., 2004; Loftsson 
and Brewster, 1996). When the complexation 
efficiency is low and a large amount of CD is 
required to obtain solid or liquid dosage forms, 
improving the complexation capacity is very 
important. Several studies have described the 
positive effect of addition of small quantities of 
water-soluble polymers in drug/cyclodextrin 
complexes, improving the complexation efficiency 
and the CD solubility (Mura et al., 2001; Partika et 
al., 2001; Ribeiro et al., 2003).  
Loftsson and cols (1994) observed a significant 
increase (about 1.7 fold) in the solubility of many 
drugs by the addition of small amounts (0.25%) of 
PVP (polyvinylpyrrolidone), CMC (sodium 
carboxymethylcellulose) or HPMC 
(hydroxypropyl methylcellulose). Mura et al., 
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(2001) observed an increase of dissolution rate of 
naproxen when complexed in a ternary system 
naproxen/HPβCD/PVP. The combined use of PVP 
and HPβCD resulted in a synergistic increasing 
effect of the aqueous solubility of NAP (120 times 
that of the pure drug). 
Pyrimethamine (PYR) (Fig. 1) is a 
diaminopyrimidine used in combination with 
sulfonamides, usually sulfadoxine or dapsone. It 
exerts antimalarial activity by inhibiting the 
plasmodial dihydrofolate reductase, thus indirectly 
blocking the synthesis of nucleic acids in malaria 
parasite. It is a slow-acting blood schizontocide, 
and could also be used for the treatment of 
toxoplasmosis (Greenwood, 2008). Due to its low 
water solubility (0.0273 mg.mL-1), high doses of 
PYR are required to provide a satisfactory 
inhibition of proliferation of the parasite. Low 
soluble drugs show bioavailability problems and 
are unpredictable and slowly absorbed when 
compared with the drugs more soluble in water 
(Carrier et al., 2007). Several studies on the 
complexation of pyrimethamine with different 
CDs have reported clear proof of these advantages 
(Araújo et al., 2007; Asbhar et al., 2009; Jansook, 
Loftsson, 2009). Little attention has been focused 
on the use of third components, such as water-
soluble polymers, for improving the properties of 
drug:CD complexes. The aim of this work was to 
prepare and to characterize the inclusion 
complexes between pyrimethamine (PYR) and 
hydroxypropyl-β-cyclodextrin (HPβCD) in the 
presence or absence of water-soluble polymers 
polyvinylpyrrolidone (PVP) and sodium 
carboxymethylcellulose (CMC). 
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Figure 1 - Chemical structure of PYR. 
 
 
MATERIAL AND METHODS 
 
Material 
Pyrimethamine was purchased from Roche S.A., 
hydroxypropyl-β-cyclodextrin was kindly 
provided by Chemyunion. Polyvinylpyrrolidone 
(Plasdone K25) and sodium 
carboxymethylcellulose was purchased from ISP 
and Wollf-Celullolsics, respectively. All other 
reagents and solvents used were of analytical 
grade.  
 
Inclusion Complex Preparation 
Binary and ternary complexes were obtained by 
two different methods: coevaporation (COE) and 
freeze-drying (LPh). Equimolar quantities of PYR 
and HPβCD were dispersed in water. Dispersions 
were homogenized on a magnetic stirrer and 
evaporated at 40°C for 56 h or frozen in an ethanol 
immersion bath at –50°C (Freezone model 
79490, Shell Freezer) and then freeze-drying 
(Lyph-lock 6 apparatus). Ternary systems 
were obtained in the same way, but the equimolar 
quantities of PYR and HPβCD were dispersed in 
0.25% (w/v) of PVP or 0.10% (w/v) of CMC 
water solutions. Physical mixtures (PM) of binary 
and ternary systems were prepared in the same 
molar ratio and compared. 
 
Phase-solubility analysis 
Phase-solubility study was conducted as described 
by Higuchi and Connors (1965). Excess amount of 
PYR was added to the aqueous solutions 
containing increasing concentrations of PVP or 
CMC (0, 0.1, 0.15, 0.20, 0.25, 0.30, 0.40 and 
0.5%) or HPβCD (0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.4, 
2.0, 4.0, 8.0 and 10.0 mmol.L-1) in the presence or 
absence of a fixed quantity of PVP (0.25%) or 
CMC (0.10%). The suspensions were equilibrated 
at 37 °C under mechanic stirring for 72 h, then 
filtered (0.45 µm pore size) and assayed by 
spectrophotometry (Beckman Coulter DU 640) at 
273 nm in triplicate. 
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Differential scanning calorimetry (DSC) 
DSC curves were obtained by conventional 
differential scanning calorimetry (DSC 50 
Shimadzu) using aluminum crucibles with 3.0 mg 
of samples, under dynamic nitrogen atmosphere 
(50 mL.min-1) and heating rate of 10ºC.min-1 in a 
temperature range of 40 to 300ºC. The DSC cell 
was calibrated with indium 99.99% pure (m.p. 
156.6 ºC; AHfus. = 28.54 J.g-1). 
 
X-ray diffractometry 
X-ray diffraction patterns were collected with a 
Shimadzu XD-6000 diffractometer in the 2 theta 
range at scan rate of 2° min-1, using polycrystalline 
silicon as reference. 
 
Dissolution Profile 
Binary and ternary system in an amount equivalent 
to 25 mg of PYR were placed in hard gelatin 
capsules and compared with capsules containing 
25 mg of PYR. Dissolution profiles were 
performed in a Hanson Research dissolutor 
(model SR II 6), according to USP 31 monograph 
(United States Pharmacopeia, 2009): apparatus 2 
(paddle), in 900 mL of HCl 0.01 N (37±0.5ºC) and 
stirred at 50 rpm. At fixed time intervals (5, 10, 
15, 20, 25, 35 and 45 min), samples were 
collected, filtered (pore size = 45 µm) and the drug 
was quantified in a spectrophotometer (Beckman 
Coulter UV-VIS DU 640), using 1 cm quartz 
glass cuvette at 273 nm. Values obtained were 
corrected considering the amounts collected and 
expressed in percentage of drug dissolved versus 
the time. Sinkers were employed to avoid capsule 
flotation in dissolution vessel. 
 
 
RESULTS AND DISCUSSION 
 
Phase-solubility analysis 
The addition of water-soluble polymers to an 
aqueous solution of drug and CD is frequently 
associated to the increase of the complex stability 
constant (KC) and to an improvement of 
complexation efficiency. Therefore, less CD is 
necessary to complex the same amount of drug 
(Loftsson, Másson e Sigurjónsdóttir, 1999). When 
polymer and CD are present in a system, it is 
expected to increase the solubility greater than for 
each individual component, demonstrating a 
synergistic effect with the formation of a new kind 
of complex, where CD is the complexing agent 
and the polymer, a co-complexant. Phase-
solubility diagrams of PYR in HPβCD solutions in 
the presence or absence of water soluble polymers 
[0.25% (w/v) PVP or 0.10% (w/v) CMC] are 
presented in Figure 2. 
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Figure 2 - Phase-solubility diagrams for PYR at room temperature in the presence of HPβCD 
without polymers and with 0.25% (w/v) PVP or 0.10% (w/v) CMC. 
 
 
Phase solubility diagrams showed a linear increase 
of PYR solubility as a function of HPβCD 
concentration and were all Higuchi AL type, 
indicating the formation of first order complex 
relative of CD and of order 1 or superior for the 
guest-molecule. Considering the formation of a 
complex with 1:1 stoichiometry, first order relative 
to CD (n = 1) and order 1 relative to PYR, the 
system could be represented by the following 
chemical equation: 
m PYR + n HPβCD →← Kc  PYRn - CDn 
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and KC value can be determined by the Higuchi 
and Connors equation (1965): 
 
( )slopeS
slopeKC
−
=
10
 
 
where S0 is the intrinsic solubility of guest-
molecule. 
A range of stability constant values of 0 to 
approximately 100.000 mol.L-1 has been reported 
for cyclodextrins complexes in the literature, with 
0 corresponding to the absence of stability 
(Rajewski and Stella, 1996). According to Pitha et 
al. (1986), only complexes showing stability 
constants (KC) between 200 to 5000 mol.L-1 could 
have practical applications; consider that label 
complexes conduct to a fast drug release and much 
stable complexes origin incomplete or delayed 
release. However, KC value is greatly affected by 
the precision of the solubility in the intercept. 
According to Loftsson et al. (2005), intrinsic 
solubility (S0) should be the same of the intercept 
solubility (Sint) defined by the equation, but for the 
drugs whose solubility is less than 0.1 mg.mL-1, 
negative deviations of intrinsic solubility are 
observed. The value of intrinsic solubility found 
for PYR was 0.1096 mM (0.0273 mg.mL-1). 
Values of -0.1160, 0.0927 and -0.2490 were 
obtained from the relation (Sint - S0)/Sint to the 
complexes PYR/HPβCD, PYR/HPβCD/CMC and 
PYR/HPβCD/PVP, respectively. In order to not 
aggregate the errors to KC values, the S0 obtained 
experimentally was used to calculate the constant 
(KC). Table 1 shows the Sint values, as well as the 
slope calculated according to phase solubility 
diagrams and stability constant (KC) for binary and 
ternary systems. 
 
Table 1 - Values of intrinsic solubility (Sint), slope of phase solubility diagrams and stability constants (KC) of PYR 
binary and ternary systems. 
Systems Sint  (mg.mL-1) Slope r2 
PYR/HPβCD 0.0241 0.1043 0.9911 
PYR/HPβCD/CMC 0.0298 0.0936 0.9933 
PYR/HPβCD/PVP 0.0205 0.0764 0.9971 
 
 
The presence of polymer did not alter the 
stoichiometry of the complex formed, which was 
1:1 for the PVP and CMC, as occurred in the 
absence of polymers. The stability constants 
obtained showed no increase in complexing 
PYR/HPβCD in the presence of polymers. This 
behavior was in good agreement with the data 
obtained for other drugs (acetazolamide, 
alprazolam, carbamazepine, dexamethazone, 
ethoxyzolamide, methazolamide, 
sulphametoxazole) in the presence of different 
polymers (Loftsson and Friodriksdottir, 1998), 
where KC values were only modified after certain 
types of treatment. 
Considering that KC for a same drug and a same 
cyclodextrin could vary according to the method 
for determination. This constant is only apparent 
and is necessary to use other ways to evaluate the 
complexation efficiency. According to Loftsson et 
al (2007), the best method to evaluate 
cyclodextrins and their potential for drug 
solubilization is the use of CE – complexation 
efficiency, that could be calculated just using the 
slope value. Based on this value, the drug:CD ratio 
can be determined, as well as the increase in the 
formulation bulk in a solid dosage form.  
The solubilizing efficiency is determined by either 
the slope of the phase-solubility profile or the 
complex to free cyclodextrin concentration ratio, 
which is referred as the complexation efficiency 
(CE) (Loftsson et al., 1999): 
 
CE = S0.K1:1 = [D/CD]/[CD] = Slope/(1 – Slope) 
 
where [D/CD] is the concentration of dissolved 
complex, [CD] the concentration of dissolved free 
cyclodextrin and Slope is the slope of the phase 
solubility profile. The CE can be used to calculate 
the D:CD ratio, which can be correlated to the 
expected increase in formulation bulk: 
 
D:CD = 1 : (1 + 1/CE) 
 
CE values and drug:CD molar ratio for binary and 
ternary system are presented in Table 2. 
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Table 2 - Complexation efficiency (CE), molar ratio (D:CD) and formulation bulk (FB, mg) for binary and ternary 
systems. 
System CE D:CD (molar) FB (mg) 
PYR:HPβCD 0.1164 1:10 1407 
PYR:HPβCD:CMC 0.1032 1:11 1547 
PYR:HPβCD:PVP 0.0828 1:13 1829 
 
 
CE values are independent of S0 and Sint. The mean 
value for CE in pure water was 0.1164 for HPβCD 
(Table 2) indicating that on the average, only 
about one out of every 10 HPβCD molecules in 
the solution were forming a water-soluble complex 
with the pyrimethamine, assuming 1:1 
drug/HPβCD complex formation. The CE values 
in Table 2 showed that on an average, addition of 
polymers to the aqueous complexation media 
decreased the complex to free cyclodextrin molar 
ratio from 1:10 to about 1:11 or 1:13. The 
correlation between the increase in the bulk 
formulation and molecular weights of the 
cyclodextrin (MWCD) and the drug (MWDrug), and 
the value of CE (Loftsson et al., 2007) would then 
be: 
 
Increase in Formulation bulk =  
MWCD/MWDrug x (1 + 1/CE) 
 
The new formulation bulk can be found by 
multiplying the number obtained with the drug 
dose (25 mg). The MW of the pyramithamine and 
natural HPβCD are 248.72 Dalton and 1.400 
Dalton, respectively. The new formulation bulk 
value is presented in Table 2. 
The use of cyclodextrins in solid dosage forms, in 
particular, is limited to low doses with relatively 
large stability constants due to the relatively large 
size of cyclodextrins molecules and mass and size 
limitations for oral dosing. Low doses are required 
for practical use of cyclodextrins in traditional oral 
dosage forms (tablets, capsules). Drug:CD ratio 
are also limited by practical dosage forms size. 
The molar ratio of Drug:CD should be in the range 
of 1:1 to 1:20 (Carrier et al., 2007). 
 
Diferential scanning calorimetry 
Figure 3 shows the thermograms for pure drug, 
HPβCD, physical mixtures, binary and ternary 
systems. The DSC curve for PYR showed an 
endothermic event at 242 °C corresponding to 
drug melting point. DSC curves for both binary 
systems, BLPh and BCOE showed an endothermic 
event between 135 and 160 °C, characteristic of 
dehydration, and another endothermic event at 
242°C, referent to drug melting point. The same 
events were observed for ternary systems prepared 
with CMC - TLPh and TCOE – an endothermic event 
between 135 and 160°C, characteristic of 
dehydration and another at 240°C, referent to PYR 
melting point. For the ternary systems prepared 
with PVP (T PVPLPh and T PVPCOE); however, 
DSC curves showed only the dehydration 
endothermic event between 100 and 147°C. As the 
thermal event referent to drug melting point was 
suppressed, the formation of true inclusion 
complexes for these systems could be suggested. 
 
X-ray diffraction 
X-ray diffraction is a simple and useful method to 
detect the complex formation between drug and 
cyclodextrin. Diffratograms corresponding to 
PYR, HPβCD and physical mixtures PYR/HPβCD 
in the presence or absence of CMC and PVP and 
for binary and ternary coevaporated and freeze-
drying systems are shown in Figure 4. 
Diffraction patterns showed high intensity at 
12.253º, 18.023º and 26.345º (2θ), indicating the 
crystallinity of PYR, while an amorphous pattern 
was observed for HPβCD, CMC and PVP. 
Physical mixtures showed the presence of low 
intensity reflections, characteristic of crystallinity 
of free drug. Diffratograms referents of all the 
binary and ternary systems with CMC showed a 
certain degree of amorphization, independent to 
the method of preparation. Only ternary systems 
with PVP showed complete amorphization, 
suggesting the formation of inclusion complexes.  
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Figure 3 - DSC curves of PYR, HPβCD, polymers PVP and CMC, physical mixtures (PM), 
coevaporated (COE) and freeze-drying (LPh) binary (B) and ternary (T) systems 
obtained in dynamic nitrogen atmosphere (100 mL.min-1) and rate heating 10°C.min-1. 
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Figure 4 - XRD patterns of PYR, HPβCD, polymers PVP and CMC, physical mixtures (PM), 
coevaporated (COE) and freeze-drying (LPh) binary (B) and ternary (T) systems.  
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Dissolution rate studies 
The mean dissolution profiles of PYR and 
corresponding binary and ternary systems are 
presented in Figure 5. 
Binary systems obtained by coevaporation (BCOE) 
and freeze-drying (BLPh) showed better dissolution 
profiles when compared to multicomponent 
systems. This phenomenon may be associated to 
the swelling effect of the polymer, and therefore to 
the formation of a high viscosity gel layer around 
powdered products, which could control the 
diffusivity of dissolved drug to the dissolution 
media (Ribeiro et al., 2005). According to Capello 
et al. (2001), water-soluble polymers interact with 
CD molecules or with drug-CD complexes, 
forming multicomponent complexes drug-CD-
polymer or co-complexes - a complex formed 
between many drug-CD binary complexes and a 
linear polymer chain [(drug-CD)n]. This aggregate 
hydrates in solution, increasing the diffusion layer 
and difficulty drug release. 
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Figure 5 - Dissolution profiles of PYR and binary and ternary systems and from binary systems 
coevaporated (BCOE) and freeze-drying (BLPh); ternary systems with CMC 
coevaporated (T CMCCOE) and freeze-drying (T CMCLPh); ternary systems with PVP 
coevaporated (T PVPCOE) and freeze-drying (T PVPLPh). The vertical bars indicate the 
relative standard deviation associated with the mean of six capsules. 
 
 
CONCLUSION 
 
Phase-solubility diagrams showed a linear increase 
of PYR solubility as a function of HPβCD 
concentration and were all of AL type, indicating 
the formation of first order complex relative of CD 
and of order 1 or superior for the guest-molecule. 
The polymers present in multicomponent system 
were not interacting s with PYR and able to 
improve its solubility and increase the stability of 
the complex. DSC curves and diffractograms 
indicated the complexation of PYR/HPβCD/PVP 
or PYR/HPβCD/CMC, obtained by coevaporation 
or freeze-drying. Binary and ternary complexes 
showed higher dissolution rate when compared 
with the pure drug and could contribute for an 
improvement in drug bioavailability. 
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